PubMed Health⌕ Search

Biomedical subjects

P Coeur

Publications and source records attributed to P Coeur.

At least 19 recordsLinked to original sources
PubMed1989

[Occurrence of a circulating anticoagulant, factor V inhibitor after surgical intervention].

A case is reported of an endogenous inhibitor to factor V occurring one month after subtotal gastrectomy and splenectomy, with peroperative radiotherapy, for gastric adenocarcinoma. Preoperative coagulation tests were normal: 31 s for activated kephalin time (control 31 s) and 93% for prothrombin level. There was a fall in this latter during the first three postoperative days. Four hundred ml plasma without cryoprotein were therefore given, bringing the coagulation tests back to the normal range. On day 25, a routine check showed an activated kephalin time of 71 s (control 31 s), a prothrombin level of 13% with a thrombin time of 18 s (control 18 s). There was no associated haemorrhagic diathesis. Measurement of all the individual coagulation factors showed that there was a fall in factor V level (0.05 IU.ml-1). A large amount of antifactor V antibody was then found (47 IU.ml-1). No treatment was undertaken, the patient being so well. Two months later, the antibody had disappeared. The usual circumstances in which this antibody can be seen and the management of the related severe haemorrhages are discussed.

Aged↗
PubMed1986

Intra-cytoplasmic crystalline inclusions in acute myeloid leukemia: a rare event.

Unusual intracytoplasmic crystal-like inclusions within granulocytic precursor cells from a patient with acute myeloid leukemia (AML) are described. Based upon their cytochemical and immunochemical properties, the possible composition and origin of these inclusions are discussed. They represent a rare event in leukemic cell metabolism since, to our knowledge, only 1 case with identical characteristics has previously been reported.

Aged↗
PubMed1986

[Assessment of the risk of postpartum thromboembolism by measuring antithrombin III levels. A false hope].

In order to predict better thrombo-embolic complications that sometimes occur after delivery, we studied the variations of antithrombin III levels (A.T. III) in 703 women, at the 8th month pregnancy (275 levels), on the first day (609 levels) and the 5th day (516 levels) after delivery. The average antithrombin III levels were respectively 90.8%, 83.4% and 98.7%. We found 120 levels (8.5%) lower than 80% (normal range for A.T. III = 80-120%), 107 of which on the first day after delivery were followed by a rapid increase to the normal range; these women however were satisfactory in the post-partum period. Therefore predicting thrombo-embolic complications in the post-partum period through A.T. III levels determination would seem to be pointless.

Adult↗
PubMed1986

[Therapeutic management of pregnancy complicated by congenital antithrombin III deficiency associated with pregnancy nephropathy].

Thrombo-embolic complications in pregnant women who have congenital antithrombin III deficiency are usually prevented by giving injections of sub-cutaneous heparin from the beginning to the end of pregnancy and with the administration of concentrated doses of antithrombin III (A.T. III) at delivery and in the following days. When we discovered a severe pre-eclampsia at the 28th week of pregnancy in a patient who had congenital deficiency of A.T. III and who had a past history of very severe thrombo-embolic complications we administered concentrated A.T. III as well as continuing the heparin treatment and anti-hypertensive treatment during the pregnancy. Severe fetal distress made us carry out a caesarean operation after 32 weeks of amenorrhoea. Delivery and the post-partum period were conducted without any complications. The newborn baby, who did not have congenital A.T. III deficiency, is very well.

Adult↗
PubMed1985

Serum vitamin K1 concentration and vitamin K-dependent clotting factor activity in maternal and fetal cord blood.

The serum concentration of phylloquinone (vitamin K1) was measured in 34 healthy mothers and in the arterial cord blood of their newborn infants. In addition, the activities of factor II and of factors VII plus X were determined simultaneously in 16 paired maternal and fetal bloods. The serum vitamin K1 concentration was similar to that of control subjects in 27 mothers: 9.03 +/- 4.9 micrograms/L (mean and SD), with a simultaneous concentration of 10.4 +/- 5.3 micrograms/L in cord blood. Six mothers exhibited high serum vitamin K1 concentrations from 40 to 240 micrograms/L (median, 82) and the concentration in cord blood ranged from 25 to 115 micrograms/L (median, 71). One mother had a normal concentration of vitamin K1: 9 micrograms/L while no vitamin K1 was detectable in the serum of her infant. The activity of factor II and factors VII plus X was 7% and 7%, respectively, in this infant and 100% in the mother. All other mothers showed normal factor II and factors VII plus X activity, while the median activity was 47% (28%-56%) for factor II and 65% (35%-100%) for factors VII plus X in cord blood. These data suggest that vitamin K1 can cross the placental barrier but not in every case. Therefore the systematic administration of vitamin K1 to the newborn infant seems to be required to prevent the occurrence of the hemorrhagic disease.

Blood Coagulation Factors↗
PubMed1984

[Evaluation of the performance of the Coagulyzer II (Lancer)].

The automation of equipment is essential in laboratories performing a large number of procedures with high precision. An evaluation of performance characteristics of a photoelectric automated coagulation instrument, the Coagulyzer II (Lancer) is reported and compared with performances of the Coag-a-pet 200.

Autoanalysis↗
PubMed1981

[Pyoderma gangrenosum and biclonal gammapathy probably due to multiple myeloma (author's transl)].

The authors report the observation of pyoderma gangrenosum (P. G.) leading to the discovery of an underlying biclonal gammapathy, which despite the absence of bony lesions, almost certainly represents a malignant myeloma. The authors have reviewed the different known associations with pyoderma gangrenosum, with special reference to benign and malignant gammapathies. Rare cases of biclonal gammapathies with pyoderma gangrenosum have been published but none of a malignant nature. This therefore appears to be the first reported cases. The authors are aware of the reported tendency of pyoderma gangrenosum lesions to appear in areas of previous trauma, as may be the case in this patient. Finally systemic corticosteroid therapy produced a rapid remission of the skin lesions, but with the reactivation of known treated pulmonary tuberculosis.

Gangrene↗